Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that their acumen with gene editing will enable them to make therapies that were impossible to conceive of just a few years ago, and they're both aiming for the same disease markets.

But as you may have heard, with the recent launch of its first gene therapy, called Casgevy, CRISPR Therapeutics is now a revenue-stage biotech, whereas Editas is still working on its first medicines in clinical trials. Could the smaller and earlier-stage business wow the market and drive significant returns for its shareholders like CRISPR Therapeutics did, or is it destined for the dustbin of once-promising biotechs?

For Editas to become the next CRISPR Therapeutics, it'll need to satisfy three conditions. First, it'll need to succeed in bringing one of its pipeline programs to the market after completing the clinical trials process and reporting data that satisfies regulators at the Food and Drug Administration (FDA) as well as elsewhere.

Continue reading

Source Fool.com